gene has been repeatedly reported as a schizophrenia risk gene in genome-wide association studies (GWAS). A polymorphism (rs1625579) at the gene has been associated with both neural activation and behavioral performance during a working memory task. This study examined 's associations with task-related (N-back working memory) fMRI, resting state fMRI, and diffusion tensor images (DTI) data in 177 healthy adults. We found less deactivation of the PCC in risk allele homozygotes (TT) as compared to the GT heterozygotes (cluster size = 630 voxels, cluster level < 0.001) during the N-back task, which replicated previous findings. Using the identified cluster within the PCC as the seed, we further found decreased functional connectivity between the PCC and the anterior cingulate cortex and its adjacent medial prefrontal cortex (ACC/MPFC) in risk allele homozygotes during both resting state (cluster size = 427 voxels, cluster level = 0.001) and the N-back task (cluster size = 73 voxels, cluster level = 0.05). Finally, an analysis of our DTI data showed decreased white matter integrity of the posterior cingulum in risk allele homozygotes (cluster size = 214 voxels, cluster level = 0.03). Taken together, rs1625579 seems to play an important role in both functional and structural connectivity between the PCC and the ACC/MPFC, which may serve as the brain mechanisms for the link between rs1625579 and schizophrenia.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6051762 | PMC |
| http://dx.doi.org/10.1016/j.nicl.2018.03.039 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Olanzapine-Induced Thrombocytopenia in a Patient With Chronic Schizophrenia: A Case Report.
Cureus
November 2024
Psychiatry, Al Amal Psychiatric Hospital, Emirates Health Services, Dubai, ARE.
Olanzapine, a second-generation antipsychotic widely used for schizophrenia, is primarily known for its efficacy in managing both positive and negative symptoms. While its metabolic side effects are well-documented, hematologic complications such as thrombocytopenia are rare and often underrecognized. A 30-year-old Middle Eastern male with a longstanding history of schizophrenia developed persistent thrombocytopenia after several years of olanzapine use, with platelet counts consistently below the normal range.
View Article and Find Full Text PDFTheory of mind in schizophrenia through a clinical liability approach: a sib-pair study.
Front Psychol
December 2024
Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.
Background: Consistent findings indicate that Theory of Mind (ToM) is impaired in schizophrenia (SZ). To investigate whether such deficits are trait- or state-dependent, we investigated if ToM is modified by clinical liability markers (such as basic symptoms and psychotic-like experiences), focusing on the analysis of unaffected siblings of individuals diagnosed with SZ.
Methods: The study included a total of 65 participants: 38 patients diagnosed with a schizophrenia-spectrum disorder and 27 healthy siblings.
Relevance of diet in schizophrenia: a review focusing on prenatal nutritional deficiency, obesity, oxidative stress and inflammation.
Front Nutr
December 2024
Department of Gastroenterology, "Grigore T. Popa" University of Medicine and Pharmacy, Iași, Romania.
Background/objectives: Schizophrenia is a complex mental disorder influenced by genetic and environmental factors, including dietary habits. Oxidative stress and inflammation play a crucial role in the pathophysiology of schizophrenia. Emerging research suggests that diet may affect schizophrenia through different biological mechanisms beyond oxidative stress and inflammation.
View Article and Find Full Text PDFCo-designing a low-intensity psychological therapy for fear of recurrence in psychosis using translational learning from fear of recurrence in oncology: protocol for intervention development for future testing in a feasibility study.
BMJ Open
December 2024
School of Health & Wellbeing, University of Glasgow, Glasgow, UK.
Introduction: Fear of recurrence is a transdiagnostic problem experienced by people with psychosis, which is associated with anxiety, depression and risk of future relapse events. Despite this, there is a lack of available psychological interventions for fear of recurrence, and psychological therapies for schizophrenia are often poorly implemented in general. However, low-intensity psychological therapy is available for people who experience fear of recurrence in the context of cancer, which means there is an opportunity to learn what has worked in a well-implemented psychological therapy to see if any learning can be adapted for schizophrenia care.
View Article and Find Full Text PDFIUPHAR Themed Review: The Gut Microbiome in Schizophrenia.
Pharmacol Res
December 2024
UniSA Clinical & Health Sciences, University of South Australia, Adelaide, South Australia 5000, Australia. Electronic address:
Gut microbial dysbiosis or altered gut microbial consortium, in schizophrenia suggests a pathogenic role through the gut-brain axis, influencing neuroinflammatory and neurotransmitter pathways critical to psychotic, affective, and cognitive symptoms. Paradoxically, conventional psychotropic interventions may exacerbate this dysbiosis, with antipsychotics, particularly olanzapine, demonstrating profound effects on microbial architecture through disruption of bacterial phyla ratios, diminished taxonomic diversity, and attenuated short-chain fatty acid synthesis. To address these challenges, novel therapeutic strategies targeting the gut microbiome, encompassing probiotic supplementation, prebiotic compounds, faecal microbiota transplantation, and rationalised co-pharmacotherapy, show promise in attenuating antipsychotic-induced metabolic disruptions while enhancing therapeutic efficacy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!